Private equity healthcare funds use platform acquisitions, which establish a position in a market, and bolt-on acquisitions, which add products or capabilities to an existing platform, for different purposes, and the diligence questions differ too. Platform deals turn on market position, clinical adoption and operating-plan realism; bolt-ons turn on integration compatibility, regulatory alignment and manufacturing fit. Running the same playbook for both can leave the most important questions for each deal type unasked.
This article sets out how the risk profile differs and how diligence can be structured for each.
Platform Acquisitions: Clinical Adoption
A platform acquisition is often a new market entry for the buyer, so its thesis rests on adoption. Diligence tends to focus on regulatory status, market size and reimbursement, and can underweight the day-to-day workflow barriers that decide whether clinicians actually use a device; see our article on the clinical adoption gap.
A cleared device with clinical benefit in controlled settings and a clear reimbursement path can still stall if it does not fit how clinicians practice. Integration with hospital IT is a common example: a monitoring platform whose data architecture needs custom work to connect to a hospital's electronic health record can see adoption slow while that work is done; see interoperability debt.
Questions for Platform Diligence
What is the realistic path to meaningful adoption among target clinicians, and over what period? What workflow changes does the device require, and do they fit how clinicians want to practice? Does the clinical evidence support the adoption rate assumed in the deal model?
For platforms, the first 100 days should include clinical workflow validation, confirming that target clinicians will use the device at scale, alongside sales, marketing and financial integration; see the first 100 days after a medtech acquisition.
Bolt-On Acquisitions: Integration Compatibility
A bolt-on joins a platform that already has market adoption, so adoption is usually not the main risk. The main questions are whether the bolt-on's regulatory status complements or conflicts with the platform's, whether manufacturing and quality systems fit together, and whether combining products creates new regulatory requirements.
Regulatory dependencies can be easy to miss. A bolt-on may have its own FDA clearance, but if integration changes its labeling, indications, design or materials, the change may require a new 510(k); FDA's final guidance on deciding when to submit a 510(k) for a change to an existing device sets out how manufacturers assess that. A deal model that assumes integration without regulatory work can be off by months.
Common Diligence Miss: Regulatory Entanglement
A bolt-on's clearance covers the device as cleared. New claims, new indications, labeling changes or design changes made during integration can require a new submission, and an internal diligence team without regulatory depth may not surface that until after close.
Bolt-on diligence should ask: Is the bolt-on's regulatory status independent of the platform's, or entangled with it? Does it share suppliers, contract manufacturers or quality systems with the platform? Can the products be combined without new FDA requirements?
Manufacturing integration deserves the same attention. If the platform is made in the US and the bolt-on overseas, combining supply chains adds complexity; if the bolt-on requires sterile manufacturing and the platform does not, the quality system may need upgrades under FDA's Quality Management System Regulation. See our manufacturing due diligence questions.
Clinical and Financial Diligence
Operating partners often bring strong financial and operational skills: cost structure, management and revenue execution. Judging whether clinicians will adopt a device calls for different experience, particularly for platform acquisitions. Internal diligence teams often combine operating partners, financial analysts and business development staff, and may not include someone who has worked in the clinical setting where the device will be used.
A clinician's read can test whether the device will change practice, whether workflow barriers are real, and whether the adoption curve in the deal model is realistic.
Findings the Investment Committee Can Use
Diligence is most useful when its findings are easy to act on. For platforms, the findings that matter most concern clinical adoption, regulatory clarity and operating-plan realism; for bolt-ons, regulatory entanglement, integration compatibility and manufacturing fit. Vantage's reports for private equity, a $20,000 Diligence Report or a $25,000 M&A Report, are reviewed by a physician and a biomedical engineer, with each factual claim cited to its source, and firms screening at volume can license Vantage through Enterprise.
The Bottom Line
Platform and bolt-on acquisitions call for different risk frameworks: platforms need clinical adoption validation and a realistic operating plan, and bolt-ons need regulatory and integration compatibility analysis. Clinical, regulatory and manufacturing expertise applied where each deal type needs it is easier to fund before close than the problems it prevents are to fix after.
References
Need a Custom Analysis?
Vantage full reports assemble the public record on a company, cite factual claims to their sources, and are reviewed by Arvind Ravinutala, MD, and Aswini Ravinutala, BME. Start with a free 20-minute call.